The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The Malaysian National Pharmaceutical Regulatory Agency approved selinexor (XPOVIO) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at
In this video interview with SOHO Insider, Guillermo García-Manero, MD, professor and chief of the Section of Myelodysplastic Syndromes and ad interim chair
In this video, the group discusses adding novel agents to frontline chemotherapy in large B-cell lymphoma, including polatuzumab vedotin with R-CHOP and bispecific
In this video interview with SOHO Insider, Pan-Yu Chen, PhD, associate director of Translational Medicine at Opna Bio, presents her ASH abstract on
In this video, the panel discusses follicular lymphoma treatment options in 2025.
"We have so much potential, so many lives dedicated to treatment and prevention of blood cancers, terabytes of data on immune function and
In this video interview with SOHO Insider, Adam Mead, MD, professor of hematology at the University of Oxford and lead author on the
In this SOHO Insider interview, Pearl van Heteren, MD, medical director in clinical development (Europe) at Miltenyi Biomedicine, discusses the DALY-2 EU trial
In this video, the group discusses approaching frontline follicular lymphoma patients, including determining patients who are high risk using symptoms and disease extent.
In this video, the group discusses managing POD24 follicular lymphoma patients, emphasizing clinical trials and preference for T-cell engaging therapies over chemotherapy and
